To fit with this hypothesis, PAPP-A, being the principal if not only IGFBP-4 protease [56], ought to be augmented in patients with IBD, but neither levels of total PAPP-A nor STC2 deviated from healthy controls at baseline. This evidence concerns the gene STC2 and inflammatory bowel disease.